The 2022 IPO market is wasting no time. Three biotechs launched their offerings on Monday, set to be the first IPOs of the new year. Trading is set for Friday. All three plan to raise more than $100 million apiece, and one is targeting a market cap of more than $1 billion.
Thanks to the recent trend of accelerated roadshows, the three deals will mark a record as the earliest IPO pricings (ex-SPAC) in a given year in at least 25 years.
As we noted in our 2021 US IPO Market Review, new issuers are starting the year on challenging footing due to recent underperformance. 94 biotechs went public in 2021; the group averaged a first-day return of 21%, but closed Monday with an average loss of -20% from the offer price.
| U.S. IPO Calendar | |||
|---|---|---|---|
| Issuer Business |
Deal Size Market Cap |
Price Range Shares Filed |
Top Bookrunners |
| Amylyx Pharmaceuticals (AMLX) Cambridge, MA |
$166M $1,127M |
$18 - $20 8,750,000 |
Goldman SVB Leerink |
| Phase 3 biotech developing therapies to treat ALS. | |||
| CinCor Pharma (CINC) Boston, MA |
$176M $594M |
$15 - $17 11,000,000 |
Morgan Stanley Jefferies |
| Phase 2 biotech developing oral treatments for hypertension and cardio-renal diseases. | |||
| Vigil Neuroscience (VIGL) Cambridge, MA |
$112M $491M |
$15 - $17 7,000,000 |
Morgan Stanley Jefferies |
| Phase 1 biotech developing antibody therapies for neurodegenerative diseases. | |||
Sign up for a free trial of our premium platform, IPO Pro. Follow us on Twitter (@IPOtweet) and register for our updates on the IPO market.
Amylyx Pharmaceuticals
Amylyx is developing oral small molecule therapies for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and a broad range of neurodegenerative diseases. The company believes its lead candidate, AMX0035, is the first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with ALS. Based on its Phase 2 data, the company submitted an NDS in Canada and an NDA to the FDA in 2021, and plans to submit an MAA in Europe in the 1Q22. While it believes it may gain approval with Phase 2 data, Amylyx also recently initiated a 48-week Phase 3 trial of AMX0035 for the treatment of ALS in the US and Europe.
Primary backers: Morningside Group, SUNU Ventures, Viking Global Investors.
CinCor Pharma
CinCor Pharma's lead candidate, CIN-107, has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. In 2021, CinCor Pharma initiated several different trials for patients suffering from hypertension as well as primary aldosteronism, or PA. The company is also exploring its utility in ameliorating complications of chronic kidney disease, or CKD, with plans to initiate trials in the first half of 2022.
Primary backers: Sofinnova Investments, Sofinnova Partners, 5AM Ventures, CinRx Pharma, General Atlantic.
Vigil Neuroscience
Vigil is utilizing a precision medicine approach to develop a pipeline of therapies, initially addressing genetically defined patient subpopulations, that it believes will activate and restore immune cell function within the brain. Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). In November 2021, the FDA cleared Vigil's IND for VGL101 in ALSP. The company initiated its first-in-human Phase 1 trial in December, and topline data is expected in the 2H22.
Primary backers: Atlas Venture, Northpond Ventures, Vida Ventures, Amgen.
